Ensuring Benefit Integrity: The Role of PBMs in the War against Fraud, Waste, and Abuse

August 15, 2023

The Unceasing Peril of Healthcare Fraud

In the ever-evolving landscape of healthcare, Pharmacy Benefits Management (PBM) companies serve as critical intermediaries, facilitating access to medications and ensuring cost-effective solutions for payers and patients alike. However, with the escalating threat of fraud, waste, and abuse in the healthcare industry, the role of PBMs in preventing, detecting, and correcting these unethical practices has never been more crucial. PBMs deliver a vital contribution in safeguarding payer interests and patient well-being through robust integrity programs.


The Unceasing Peril of Healthcare Fraud

Healthcare fraud continues to present a significant challenge in the United States and globally. The National Health Care Anti-Fraud Association (NHCAA) estimates that healthcare fraud costs the U.S. healthcare system tens of billions of dollars each year 1 , impacting both private and public payers. This staggering figure highlights the urgency of implementing robust measures to combat fraudulent activities and protect the integrity of the healthcare system.


The U.S. Department of Health and Human Services reported that in 2020, the total estimated improper payment in the Medicare program was $28.9 billion 2 , with a significant portion attributed to fraud. According to a report by the U.S. Government Accountability Office (GAO), improper payments under Medicare Part D reached $4.9 billion in 2020 3 .


The PBM's Role in Preventing Fraud, Waste, and Abuse:


  • Contractual Oversight: Serving as representatives for payers, PBMs negotiate and oversee contracts with pharmacies, drug manufacturers, and healthcare providers. With a thorough focus  on contractual compliance, PBMs ensure all parties adhere to ethical and legal standards, effectively reducing the potential for fraudulent activities.


  • Transparent Pricing: PBMs hold a vital responsibility in establishing drug pricing and reimbursement rates. Their commitment to transparency and fair negotiations helps diminish the motivation for pharmacies to participate in fraudulent billing practices or manipulate prices. As a result, the system is fortified against unethical behaviors, ensuring equitable access to medications for all stakeholders involved.


  • Fraud Detection Algorithms: By harnessing cutting-edge technology, PBMs utilize sophisticated fraud detection algorithms that scrutinize prescription claims and other data to detect patterns suggestive of fraudulent activities. Swift identification facilitates prompt intervention, mitigating financial losses for payers and safeguarding the integrity of the system.


  • Prior Authorization: PBMs design prior authorization procedures to confirm medical necessity and compliance with established criteria for prescribed medications. This measure effectively decreases the risk of medication abuse and inappropriate utilization, ensuring that patients receive appropriate and essential treatments.


  • Network Credentialing: PBMs conduct stringent credentialing processes for pharmacies and healthcare providers in their networks. Through verifying qualifications and legitimacy, they shield payers from fraudulent entities seeking to take advantage of the system. This rigorous approach ensures the integrity and trustworthiness of the network, safeguarding the interests of all involved parties.


  • Pharmacy Audits: PBMs perform thorough examinations of pharmacy claims to confirm adherence to contractual terms, industry regulations, and correct billing procedures. These audits involve verifying drug pricing accuracy, adherence to formularies, and appropriate medication usage. Additionally, PBMs use these reviews to detect and prevent instances of fraud, waste, and abuse within the pharmacy benefits management system.


MC-Rx’s Benefit Integrity Program: A Beacon of Ethical Practices

At MC-Rx, we take pride in our unwavering commitment to integrity, transparency, and ethical practices. Our integrity program is designed to address the specific needs of payers, offering a multi-faceted approach to prevent, detect, and correct fraud, waste, and abuse. Our program highlights include:


  • Real-time Monitoring: Our state-of-the-art fraud detection algorithms continuously monitor prescription claims, identifying anomalies and suspicious activities promptly.
  • Dedicated Fraud Investigation Team: MC-Rx has a dedicated team of experts skilled in investigating potential fraud, waste and abuse. Their vigilance ensures that any potentially fraudulent activities are swiftly detected and reported to appropriate authorities.
  • Extensive Auditing: We conduct regular audits of pharmacy claims, ensuring compliance with contractual terms and industry regulations.
  • Training and Education: Our Benefit Integrity Program includes comprehensive training for employees, pharmacies, and related entities to increase awareness of fraud, waste, and abuse, empowering them to uphold ethical standards.
  • Collaborative Efforts: We work closely with law enforcement agencies, payers, regulatory bodies, and industry stakeholders to share insights and combat fraudulent activities collectively.

 

As healthcare continues to evolve, MC-Rx stands at the forefront of safeguarding the integrity of the pharmacy benefits. By actively preventing, detecting, and correcting fraud, waste, and abuse on behalf of payers, MC-Rx plays a pivotal role in promoting transparency, cost-effectiveness, and patient-centric care. At MC-Rx, our robust Benefit Integrity Program exemplifies our dedication to upholding ethical practices and protecting the interests of both payers and patients. Together with collaborative efforts from all stakeholders, we can fortify the healthcare system against the threats of fraud, waste, and abuse, ensuring a healthier and more sustainable future for all.



References:

1 https://www.nhcaa.org/tools-insights/about-health-care-fraud/the-challenge-of-health-care-fraud/

2 https://www.cms.gov/newsroom/press-releases/fiscal-year-fy-2019-medicare-fee-service-improper-payment-

rate-lowest-2010-while-data-points

3 https://www.gao.gov/highrisk/medicare_program/why_did_study

A stethoscope is laying on a piece of paper next to a pen
December 12, 2024
URAC accreditation reflects ProCare Rx’s commitment to achieving and maintaining the highest quality, member engagement and experience, and operational standards for PBMs in the industry
By Mc-Rx Team November 15, 2024
Mental health parity and medication adherence
By MC-Rx Clinical Team August 7, 2024
Understanding GLP-1 Medications The landscape of obesity management is evolving, with GLP-1 receptor agonist (RA) medications emerging as a significant player. These FDA-approved drugs have proven effective in helping individuals lose weight, prompting a shift in how they are viewed and covered by health plans. However, the cost implications and strategic decisions surrounding these medications require careful consideration by employer groups and their members. The Case for GLP-1 Medications GLP-1 RAs, originally developed for diabetes management, have shown remarkable efficacy in weight loss. With the growing prevalence of obesity and its associated healthcare costs, there's increasing pressure on health plans to cover these medications. Despite their high cost—annual retail pharmacy expenses can exceed $10,000 per patient—GLP-1 RAs offer potential downstream savings by reducing obesity-related comorbidities such as diabetes, hypertension, and cardiovascular disease​​. Balancing Coverage and Cost Historically, weight loss medications were deemed "lifestyle" drugs and excluded from coverage. However, the rising popularity of GLP-1 RAs and their demonstrated benefits are challenging this perspective. For plan sponsors, the decision to cover these medications involves balancing the high upfront costs with the potential for long-term savings on medical expenses related to obesity. Cost-Containment Strategies For payers choosing to cover GLP-1 medications, several cost-containment strategies can be employed: Formulary Management : Deciding on the placement of these medications within the formulary is crucial. Options range from not covering the drugs to placing them on a high-cost tier with patient cost-sharing. Prior Authorization and Step Therapy : Implementing these measures ensures that only patients with a proper diagnosis (e.g., ICD-10 code for obesity) access these medications, preventing misuse and overutilization. Prerequisite Programs : Requiring participation in wellness or nutrition programs before approving weight loss medications can encourage lifestyle modifications that complement pharmacological treatment. Specialist Restrictions : Limiting prescriptions to weight loss specialists, such as bariatric doctors or endocrinologists, ensures appropriate therapy and monitoring. Duration Limits : Establishing treatment guidelines, such as discontinuing medications if a target weight loss is not achieved within six months, helps manage long-term costs​​. The Role of Brokers and Employer Groups Brokers play a pivotal role in guiding employer groups through the complexities of covering GLP-1 medications. Understanding the cost-benefit dynamics and available cost-containment strategies enables brokers to provide informed recommendations that align with their clients' financial and health objectives. Employer groups, in turn, must weigh the potential benefits of covering these medications against their budgetary constraints and the overall well-being of their workforce. Member Education and Engagement Effective communication with members is essential to ensure they understand the coverage options and adhere to prescribed treatments. Educational initiatives can include: Patient Communication Programs : Providing information on medication adherence, compliance, and lifestyle modifications. Continuing Education : Ongoing programs to keep members informed about the benefits and proper use of weight loss medications. Monitoring and Support : Utilizing pharmacy and medical data to track outcomes and adjust strategies as needed​​. Balance the Scale with Expert Guidance from MC-Rx The adoption of GLP-1 medications for weight loss represents a significant advancement in obesity management. However, the high costs associated with these drugs necessitate careful planning and strategic implementation by brokers, employer groups, and members. By employing robust cost-containment strategies and prioritizing member education, health plans can navigate the financial challenges while delivering meaningful health benefits to their populations. MC-Rx, as a full-service pharmacy benefits manager, offers the expertise and tools to help clients optimize their coverage decisions and manage the complexities of incorporating GLP-1 medications into their health plans. Here are just a few of the GLP-1 strategies we use to shield our clients from excessive costs: Implementation of Drug Management Tools, which is critical to ensure proper utilization for GLP-1s. Strategic Benefit Design, which also protects clients from improper GLP-1 utilization. Clear Member Communication, which is crucial for proper adherence and compliance. When implemented with an existing client, the above-listed strategies helped them achieve $382,000 in cost avoidance for GLP-1s. With the right approach, the benefits of these medications can be realized, contributing to better health outcomes and potentially lowering overall healthcare costs in the long run. For more information on managing GLP-1 medications and other pharmacy benefits, reach out to an MC-Rx expert today .
By MC-Rx Clinical Team August 2, 2024
Mental Health Parity and Medication Adherence
March 21, 2024
MC-Rx, powered by ProCare Rx, has been notified by the Academy of Managed Care Pharmacy (AMCP) of the acceptance of their abstract, “Improving Adherence to HIV PREP via a PBM-Driven Educational Intervention” , for presentation at AMCP 2024 Conference in April.
February 23, 2024
Exploring the rising costs and demands of weight-loss medication and how to combat those costs, significantly lowering drug costs for payors and increasing access for patients who need them.
January 16, 2024
A message from Marileny Lugo, President, MC-Rx
January 16, 2024
A message from Marileny Lugo, President, MC-Rx
January 10, 2024
To decrease the burden on healthcare costs, at MC-Rx we strive to create awareness by educating our community regarding the importance of prevention.
September 28, 2023
Increased medication adherence has been linked to better clinical and financial outcomes.
More Posts
Share by: